Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.

ARDS, Human

Covid-19

Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.

Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords

Instituto de Medicina Regenerativa

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19

Number of patients with changes in percentage of resting Oxygen saturation (%O2)

Changes in mmHg of Arterial partial pressure of oxygen / Fraction of inspiration O2 (PaO2/FiO2) in all participants

Changes in percentage of participants with reduction in bilateral ground-glass opacities

Changes in percentage of participants with reduction of pneumonia bilateral infiltration

Number of participants with a reduction in Lactate dehydrogenase (mg/dL)

Number of participants with a reduction in C-reactive protein (mg/dL)

Number of participants with a reduction in D-dimer (mg/dL)

Number of participants with a reduction in Ferritine (mg/dL)

Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.

Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.

Pancreatitis

Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.

Aggressive Intravenous Hydration Group

Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.

Standard Fluids Arm

Los Angeles County Hospital

Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis

Feasibility Study of a Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis

The primary endpoint is post ERCP pancreatitis which is defined as increased abdominal pain and a serum amylase level three times the upper limit of normal (3xULN). Increased pain will be defined as an increase in the visual analog pain score compared to the value immediately prior to ERCP

Clinical volume overload will be defined by physical findings of lower extremity edema and pulmonary rales.

Serum amylase three times the upper limit of normal is a secondary outcome measure.

Increased abdominal pain is defined as an increase in abdominal pain based on the visual analogue score following the ERCP compared to the score immediately prior to the ERCP.

tachycardia/protease

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus